People: Novavax Inc (NVAX.O)

NVAX.O on Consolidated Issue listed on NASDAQ Global Market

2.05USD
9 Feb 2010
Price Change (% chg)

$-0.04 (-1.91%)
Prev Close
$2.05
Open
--
Day's High
$2.14
Day's Low
$1.99
Volume
1,083,848
Avg. Vol
1,410,200
52-wk High
$7.79
52-wk Low
$0.52

view people for:

Summary

Name Age Since Current Position
Lambert, John 56 2007 Executive Chairman of the Board
Singhvi, Rahul 44 2005 President, Chief Executive Officer, Director
Driscoll, Frederick 57 2009 Chief Financial Officer, Vice President, Chief Accounting Officer, Treasurer
Hage, Raymond 41 2006 Senior Vice President - Commercial Operations
Trizzino, John 2009 Senior Vice President - International and Government Alliances
Johnston, Thomas 38 2008 Vice President - Strategy
Evans, Gary 52 2007 Lead Independent Director
Marsh, John 82 1997 Director
McManus, Michael 66 1998 Director
Modi, Rajiv 49 2009 Director
Erck, Stanley 60 2009 Director
» Insider Trading

Biographies

Name Description
Lambert, John Mr. John Lambert is Executive Chairman of the Board of Directors of Novavax, Inc. since March 2007. Independent consultant with JG Solutions Limited from 2005 to 2007. President, Chiron Vaccines, a biopharmaceutical company, from 2001 to 2005. Currently the Chairman of the Conseil d’Administration of Farmaprojects S.A. (Spain), Non-Executive Chairman of Cambridge Biostability Ltd. (U.K) and a non-executive board member of Acambis plc.
Singhvi, Rahul Mr. Rahul Singhvi is President, Chief Executive Officer and Director of Novavax, Inc. since August 2005. Senior Vice President and Chief Operating Officer of Novavax from April 2005 to August 2005 and Vice President — Pharmaceutical Development and Manufacturing Operations from April 2004 to April 2005. For ten years prior to joining the Company, served in several positions with Merck & Co., Inc., culminating as Director with the Merck Manufacturing Division from 1999 to 2004.
Driscoll, Frederick Mr. Frederick W. Driscoll serves as Chief Financial Officer, Vice President, Chief Accounting Officer, Treasurer of Novavax, Inc. Previously Mr. Driscoll served as Chief Financial Officer, and President and Chief Executive Officer of Genelabs Technologies, Inc. Prior to his position at Genelabs, Mr. Driscoll served in a variety of financial and senior management positions at Astraris, Inc., OXiGENE, Inc. and Collagenesis Corp. He also spent more than twenty years with Instrumentation Laboratory as vice president of finance for the Americas. Mr. Driscoll received his bachelor's degree in accounting from Bentley College.
Hage, Raymond Raymond J. Hage, Jr. serves as Senior Vice President, Commercial Operations of Novavax, Inc. since October 2006. Senior Vice President and Chief Operating Officer from August 2005 to October 2006 and Vice President of Marketing and Corporate Development of Novavax from January 2004 to August 2005. Prior to joining the Company, served in several positions including an independent marketing consultant with CHS, Inc. in 2003, Director of Marketing with Cephalon, Inc. from 2002 to 2003 and for 10 years held various marketing and sales roles at Eli Lilly culminating as Director of US Women’s Health from 2001 to 2002.
Trizzino, John Mr. John J. Trizzino is Senior Vice President - International and Government Alliances of Novavax, Inc. Previously, Mr. Trizzino was Vice President of the vaccine franchise at MedImmune, Inc., Senior Vice President of business development at ID Biomedical, and served as Vice President within the Henry Schein, Inc. medical division in business development and General Manager of their GIV division. Mr. Trizzino is a graduate of Long Island University and received his master's degree in business administration from New York University's Stern School of Business.
Johnston, Thomas Thomas Johnston is Vice President, Strategy of Novavax, Inc. since April 2008. Prior to joining the Company in March 2007, and from August 2003 served as independent strategic business consultant and Gemalto employee for multiple industries including banking, government security and mobile telecommunications. Prior to this, served as VP of Emerging Technology for Fleet Bank, and additional roles within Microsoft Corporation and Comcast Corporation.
Evans, Gary Mr. Gary C. Evans is Lead Independent Director of Novavax, Inc. since March 2007. Chairman of the Board of Directors of Novavax from April 2005 to March 2007. Chief Executive Officer of GreenHunter Energy, Inc. and Orion Ethanol, Inc., two publicly traded alternative energy companies. Chairman of Global Hunter Holdings, LP, since June 2005. Chairman, President and Chief Executive Officer of Magnum Hunter Resources, Inc., an oil and gas exploration and production company, from 1995 to 2005. Chairman of the Board of Directors and Chief Executive Officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Currently a trustee of TEL Offshore Trust, a publicly traded oil and gas trust.
Marsh, John Mr. John O. Marsh, Jr. is Director of Novavax, Inc. He is Co-Chair of Independent Review Group for Walter Reed Hospital and Bethesda Navy Medical Center since 2007. Visiting Professor, George Mason University, since 2001. Visiting Professor, Virginia Military Institute, 1998. Interim Chief Executive Officer of Novavax from July 1996 to March 1997 and Chairman of the Board of Directors from July 1996 to February 1997. Secretary of the Army from 1981 to 1989. Counselor with Cabinet rank to the President of the United States from 1974 to 1977. Assistant for National Security Affairs to Vice President of the United States, 1974. Assistant Secretary of Defense from 1973 to 1974. U.S. Representative in Congress from 1963 to 1971.
McManus, Michael Mr. Michael A. McManus, Jr is Director of Novavax, Inc. He is President, Chief Executive Officer and Director of Misonix, Inc., a medical, scientific and industrial provider of ultrasonic and air pollution systems, since 1998. President and Chief Executive Officer of N.Y. Bancorp from 1990 to 1998. Assistant to the President of the United States from 1982 to 1985. Currently a director of American Home Mortgage Holdings, Inc. and A. Schutman Inc.
Modi, Rajiv Dr. Rajiv I. Modi, Ph.D. is Director of Novavax, Inc on April 1, 2009. He is Managing Director of Cadila Pharmaceuticals, Ltd., a company organized in India, since 1995. Director of other Cadila Group Companies.
Erck, Stanley Mr. Stanley Erck is Director of Novavax, Inc. Mr. Erck has more than twenty five years of experience in the biotechnology and health-care industries and served most recently as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies that was acquired in 2008 by Intercell. Previously, Mr. Erck was President and Chief Executive Officer of Procept, a publicly traded immunology company, Vice President of Corporate Development at Integrated Genetics (now Genzyme), and in management positions at Baxter International. Mr. Erck is also a Director of BioCryst Pharmaceuticals, MaxCyte, Inc. and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his masters in business administration from the University of Chicago.

Basic Compensation

Name Fiscal Year Total
Lambert, John --
Singhvi, Rahul 707,707
Driscoll, Frederick --
Hage, Raymond 403,960
Trizzino, John --
Johnston, Thomas --
Evans, Gary --
Marsh, John --
McManus, Michael --
Modi, Rajiv --
Erck, Stanley --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Lambert, John 0 0
Singhvi, Rahul 860,000 1,914,600
Driscoll, Frederick 0 0
Hage, Raymond 335,000 669,950
Trizzino, John 0 0
Johnston, Thomas 0 0
Evans, Gary 0 0
Marsh, John 0 0
McManus, Michael 0 0
Modi, Rajiv 0 0
Erck, Stanley 0 0

Insider Trading

Name Shares Traded Price
DRISCOLL FREDERICK W 10,000 $0.00
LAMBERT JOHN A 3,400 $2.82
HAGE RAYMOND JOSEPH 1,392 $2.88
HEATON PENNY 8,333 $2.86
HAGE RAYMOND JOSEPH 30,030 $2.81
LAMBERT JOHN A 400 $2.85
SINGHVI RAHUL 50,000 $3.00
LAMBERT JOHN A 7,400 $2.80
HAGE RAYMOND JOSEPH 29,734 $2.85
HAGE RAYMOND JOSEPH 19,200 $2.79
LAMBERT JOHN A 4,500 $2.83
HAGE RAYMOND JOSEPH 708 $2.89
LAMBERT JOHN A 200 $2.76
HAGE RAYMOND JOSEPH 5,136 $2.82
HAGE RAYMOND JOSEPH 24,138 $2.80
LAMBERT JOHN A 5,500 $2.86
LAMBERT JOHN A 9,146 $2.81
HAGE RAYMOND JOSEPH 1,500 $2.86
HAGE RAYMOND JOSEPH 10,300 $2.80
LAMBERT JOHN A 2,900 $2.84
HAGE RAYMOND JOSEPH 100,000 $0.74
LAMBERT JOHN A 1,300 $2.77
HAGE RAYMOND JOSEPH 2,000 $2.84
HAGE RAYMOND JOSEPH 37,884 $3.05
HAGE RAYMOND JOSEPH 5,200 $3.08
» Full list on Insider Trading
view people for: